临床研究

以疾病的诊断、治疗、预后、病因为目标;以病人为对象;以群体研究为主要研究方法;以医疗机构为基地的一类医学研究的总称。通过临床研究获得治疗方法的安全性和有效性。在群体中进行药物测试,以期获得剂量、药物作用、不良反应等相关资料,从而对治疗方法进行安全性有效性评价。

新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 临床研究 » Pharma Rev:鱼类多肽或可有效治疗心血管疾病

Pharma Rev:鱼类多肽或可有效治疗心血管疾病

来源:生物谷 2015-01-14 10:08

2015年1月14日 讯 /生物谷BIOON/ --近日,发表在国际杂志Pharmacological Reviews上的一篇综述文章中,来自莱斯特大学的研究人员表示,来源于鱼类机体中的多肽或可用于有效治疗心血管疾病。

文章中,研究者David Lambert表示,我们首次从硬骨鱼中分离出了一种名为硬骨鱼紧张肽II(UII),其可以激活一种名为UT的G蛋白偶联受体,从而调节包括细胞内钙质在内的一系列信号路径的激活;更有意思的是这种多肽可以收缩血管。

研究者发现,UII可以调节包括心血管系统、肾脏及中枢神经系统在内的一系列系统的生物学活性。

Lambert教授表示,我们已经对这种名为UII的多肽进行了很多年的研究了,其可以表现出一种非常有意思及其潜在的药理学特性,后期我们将以此为基础涉及新型的小分子药物,并对其进行评估,以期待其早日用于治疗一系列心血管疾病中去。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

Hubert Vaudry, Jérôme Leprince, David Chatenet, Alain Fournier, David G. Lambert, Jean-Claude Le Mével, Eliot H. Ohlstein, Adel Schwertani, Hervé Tostivint, and David Vaudry

Urotensin II (UII) is a cyclic neuropeptide that was first isolated from the urophysis of teleost fish on the basis of its ability to contract the hindgut. Subsequently, UII was characterized in tetrapods including humans. Phylogenetic studies and synteny analysis indicate that UII and its paralogous peptide urotensin II-related peptide (URP) belong to the somatostatin/cortistatin superfamily. In mammals, the UII and URP genes are primarily expressed in cholinergic neurons of the brainstem and spinal cord. UII and URP mRNAs are also present in various organs notably in the cardiovascular, renal, and endocrine systems. UII and URP activate a common G protein–coupled receptor, called UT, that exhibits relatively high sequence identity with somatostatin, opioid, and galanin receptors. The UT gene is widely expressed in the central nervous system (CNS) and in peripheral tissues including the retina, heart, vascular bed, lung, kidney, adrenal medulla, and skeletal muscle. Structure-activity relationship studies and NMR conformational analysis have led to the rational design of a number of peptidic and nonpeptidic UT agonists and antagonists. Consistent with the wide distribution of UT, UII has now been shown to exert a large array of biologic activities, in particular in the CNS, the cardiovascular system, and the kidney. Here, we review the current knowledge concerning the pleiotropic actions of UII and discusses the possible use of antagonists for future therapeutic applications.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!



相关阅读

相关标签

最新会议 培训班 期刊库